Antihypertensive drugs associated with cough
Pro Research Analysisby 
Searched over 200M research papers
ACE Inhibitors and Cough: Key Antihypertensive Drug Association
Cough is a well-known side effect of angiotensin-converting enzyme inhibitors (ACE inhibitors or ACEIs), a common class of antihypertensive drugs. Studies consistently show that ACEIs are much more likely to cause cough compared to other antihypertensive agents such as angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) Hu2023Ravid1994Israili1992+4 MORE. The risk of developing a cough with ACEIs is significantly higher than with placebo, ARBs, or CCBs, with some studies reporting a relative risk up to five times greater compared to CCBs .
Incidence and Risk Factors for ACE Inhibitor-Induced Cough
The incidence of cough among patients taking ACEIs varies widely, ranging from about 5% to 35% depending on the population and study design Israili1992Bezalel2015. In older adults, the prevalence of ACE inhibitor-induced cough can be as high as 19% . Certain factors, such as female gender, use of specific antidepressants (SNRIs), and gastroesophageal reflux disease (GERD), may increase the risk of developing this side effect Israili1992Turrin2021. The cough is typically dry and persistent, and it often recurs if the patient is switched to another ACEI Ravid1994Israili1992Borghi2023+1 MORE.
Comparison with Other Antihypertensive Drugs
ARBs and CCBs are associated with a much lower risk of cough compared to ACEIs Hu2023Wu2004Bezalel2015. For example, in direct comparisons, patients on ARBs or CCBs rarely report cough as a side effect, making these drugs suitable alternatives for patients who develop cough on ACEIs Hu2023Wu2004Bezalel2015. In one study, losartan (an ARB) and amlodipine (a CCB) had significantly fewer reports of cough compared to lisinopril (an ACEI), where coughing was a common complaint .
Mechanism of ACE Inhibitor-Induced Cough
The cough associated with ACEIs is believed to be caused by the accumulation of bradykinin and substance P, which are normally broken down by the angiotensin-converting enzyme. When this enzyme is inhibited, these substances build up in the respiratory tract, leading to a dry, persistent cough Israili1992Borghi2023Esam2020+1 MORE. This mechanism is unique to ACEIs and does not occur with ARBs or CCBs, explaining the difference in side effect profiles Hu2023Borghi2023Bezalel2015.
Management and Recommendations
If a patient develops a cough while taking an ACEI, guidelines recommend switching to an ARB or CCB rather than trying another ACEI, as the cough is considered a class effect and likely to recur with any ACEI Ravid1994Israili1992Borghi2023+1 MORE. In some cases, the cough may diminish over time, but for many patients, discontinuation of the ACEI is necessary Ravid1994Israili1992. There is also emerging interest in potential treatments, such as bromelain-containing nutraceuticals, to manage ACEI-induced cough, though more research is needed .
Other Antihypertensive Drugs and Cough
While cough is most strongly associated with ACEIs, other antihypertensive drugs, such as thiazide diuretics (when combined with ACEIs), may also contribute to cough, but this is much less common . CCBs and ARBs are generally not associated with cough as a side effect Hu2023Wu2004Bezalel2015.
Conclusion
Cough is a common and sometimes troublesome side effect of ACE inhibitors, affecting up to one in five patients depending on the population. The risk is much lower with ARBs and CCBs, making them preferred alternatives for patients who develop cough on ACEIs. The mechanism involves the accumulation of bradykinin and substance P, and the cough usually recurs if another ACEI is tried. Recognizing and managing this side effect is important for optimizing antihypertensive therapy and patient comfort Hu2023Ravid1994Israili1992+4 MORE.
Sources and full results
Most relevant research papers on this topic